ARS Pharmaceuticals, Inc. SPRY
3.95 USD +0.38 (+10.64%)
At closeNov 11, 2026, 7:52 PM EST
3.92 -0.03 -0.77%
After hours · Nov 11, 7:52 PM ET
3.57 Day range 4.13
2.44 52-week range 13.15
- YTD
- -66.09%
- 1 year
- -54.96%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
defenseworld.net CenterBook Partners LP Buys 295,532 Shares of ARS Pharmaceuticals, Inc. $SPRY CenterBook Partners LP raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 239.1% in the third quarter, according to the company in its most recent filing with the Securities…
benzinga.com ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results ARS Pharmaceuticals (NASDAQ:SPRY) on Thursday reported weaker-than-expected results for the third quarter.
benzinga.com ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results ARS Pharma missed Q3 earnings and sales estimates; shares rose 5.6% premarket as analysts cut price targets despite neffy progress.
seekingalpha.com ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer…
benzinga.com Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Lowers Price Target to $20 Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and lowers the price target from $30 to $20.
benzinga.com Raymond James Downgrades ARS Pharmaceuticals to Outperform, Lowers Price Target to $17 Raymond James analyst Ryan Deschner downgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Strong Buy to Outperform and lowers the price target from $28 to $17.
marketbeat.com ARS Pharmaceuticals Q3 Earnings Call Highlights ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow…
zacks.com ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.52 per share a year ago.
benzinga.com ARS Pharmaceuticals Q3 2026 Earnings Call Transcript ARS Pharmaceuticals (NASDAQ:SPRY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com ARS Pharmaceuticals Q3 EPS $(0.36) Misses $(0.31) Estimate, Sales $37.710M Miss $41.992M Estimate ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 30.77 percent increase over losses…
seekingalpha.com ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling ARS Pharmaceuticals is rated Buy, with current market pricing disconnected from fundamental pipeline value despite commercial setbacks. neffy, the flagship intranasal epinephrine spray, faces slow…
zacks.com ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com ARS Pharma to Report Third Quarter 2026 Financial Results SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
gurufocus.com SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law [url="]Schall, Brown and Schwartz LLP[/url] (âSBSâ), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Ph
businesswire.com SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.
businesswire.com SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 NEW YORK--(BUSINESS WIRE)---- $SPRY #ARS--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("“ARS Pharmaceuticals” or…
gurufocus.com SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawPR NewswireLOS ANGELES, Oct. 5, 2026LOS ANGELES, Oct. 5,
gurufocus.com ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRYPR NewswireNEW YORK, Oct. 5, 2026NEW YORK,
prnewswire.com ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY NEW YORK, Oct. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) violations of §§10(b)…
prnewswire.com SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Oct. 5, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals,…
newsfilecorp.com ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between…
newsfilecorp.com SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you…
newsfilecorp.com SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you…
newsfilecorp.com ARS PHARMACEUTICALS DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between…
prnewswire.com ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June…
benzinga.com Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mixed, Dow down 0.1%. Swarmer Inc (NASDAQ: SWMR) shares drop 7% after reporting worse-than-expected financial results.
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
benzinga.com ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ARS Pharmaceuticals (NASDAQ:SPRY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
benzinga.com ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.48) by 31.25 percent. This is a 36.96 percent decrease over losses…
benzinga.com Can ARS Pharma's New CEO Unlock Neffy's Potential? ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.
benzinga.com ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective July 7 ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to…
benzinga.com Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
benzinga.com ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
benzinga.com Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, while consumer discretionary fell 1.1%. Core PCE rose 3.4% in May.
benzinga.com Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24 Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.
benzinga.com H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…
benzinga.com Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3 results and issuing strong guidance. Autozi Internet Technology, Focus Universal, SAGTEC GLOBAL,…
benzinga.com ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.- benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
benzinga.com ARS Pharma Lowers 2026 Cash Operating Expense Guidance To $248M And Reaffirms Path To Cash-Flow Breakeven In 2027 No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future…
benzinga.com ARS Pharmaceuticals Continues To Reduce Cash-Based Operating Expenses After No New Commercial Formulary Additions Or Coverage Decisions Have Been Issued For Neffy In The Latest Cycle Access and payer coverage: Despite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy…
benzinga.com Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30 Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.- benzinga.com ARS Pharmaceuticals Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 74.29 percent decrease over losses…